Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.



PPMI Enrollment Status

76%
Genetic Cohort Participants
Enrollment Goal: 600

77%
Genetic Registry Participants
Enrollment Goal: ~600

100%
De Novo PD Participants
Enrollment: 424

100%
Control Participants
Enrollment: 196

100%
Subjects with SWEDD
Enrollment: 64

100%
Prodromal Participants
Enrollment: 65

Last Update: September 5 2017

 

More about study cohorts >

A Landmark Study of Parkinson’s Disease

The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.

LATEST NEWS FROM PPMI

Participant Update Call – 6/28/2017

All PPMI participants are encouraged to call in for our quarterly study update call, tomorrow at 12 pm EST. Dr. Daniel Weintraub will discuss the impact of PD on cognition. Dr. Weintraub’s talk will center around his recent publication of PPMI data in the journal PLoS One. You can read the full research article online.


PPMI at MDS 2017

The 21st International Congress of Parkinson’s Disease and Movement Disorders (MDS) conference will take place next week, June 4-8, in Vancouver, Canada. PPMI leadership is happy to announce that several posters will feature PPMI data. We invite you to look for PPMI at this year’s meeting:   Blue Ribbon Highlight:  840 “Multiple modality biomarker prediction […]


PPMI 2017 Annual Meeting Summary

Nearly 180 PPMI investigators, coordinators, study cores, patient advisory and steering committee members, sponsors, and industry partners from around the world met in New York City May 3-4, 2017 to share PPMI study and scientific updates and to discuss the future of the initiative.  The annual meeting remains a critical component to the study. It […]


PPMI iPSC Lines — A Valuable Tool for Researchers

The Parkinson’s Progression Markers Initiative (PPMI) has expanded to include the generation of induced pluripotent stem cell (iPSC) lines from reprogrammed peripheral mononuclear blood cells (PBMCs) collected from PPMI participants. Study leadership hopes to complete 135 blood collections by the end of 2017; to date, over 50 PPMI participants have given blood samples. Cells lines […]


Live Webinar February 24: 2016 PPMI Data Challenge Winners

In June of 2016, The Michael J. Fox Foundation challenged data scientists and computational analysts to work with PPMI’s unprecedented collection of open-access clinical, molecular, and imaging data to answer two fundamental questions about Parkinson’s disease: what are the subtypes of the disease, and what baseline factors predict disease progression? In total, forty researchers submitted […]


Learn More